Immunome

IMNM · NASDAQ

$17.92+$1.15 (+6.86%)TodayMarket closed · Oct 20, 7:54 PM ET

Prev close $16.77

Latest news

Press releaseOct 6, 4:02 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 30, 7:45 AM ETBusiness Wire
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
NewsSep 9, 8:02 AM ETAvi Kapoor
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Press releaseSep 8, 4:02 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 2, 7:45 AM ETBusiness Wire
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Press releaseAug 11, 4:02 PM ETBusiness Wire
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseAug 6, 4:02 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsAug 5, 8:03 AM ETAvi Kapoor
SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Press releaseJul 20, 7:30 AM ETBusiness Wire
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
NewsJul 8, 1:18 PM ETVandana Singh
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review
Press releaseJul 8, 7:30 AM ETBusiness Wire
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Press releaseJul 7, 4:02 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 11, 7:30 AM ETBusiness Wire
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Press releaseJun 4, 4:02 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 30, 8:00 AM ETBusiness Wire
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Press releaseMay 27, 8:00 AM ETBusiness Wire
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseMay 12, 4:02 PM ETBusiness Wire
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Press releaseMay 5, 4:00 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseApr 29, 7:30 AM ETBusiness Wire
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Press releaseApr 21, 10:30 AM ETBusiness Wire
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Press releaseApr 2, 4:00 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMar 5, 4:00 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMar 3, 4:46 PM ET
Immunome: Q4 Earnings Insights
Press releaseMar 3, 4:02 PM ETBusiness Wire
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
Press releaseFeb 23, 8:00 AM ETBusiness Wire
Immunome to Present at Upcoming Investor Conferences
Press releaseFeb 5, 4:00 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseFeb 5, 9:26 AM ETGlobe Newswire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Press releaseFeb 4, 8:00 AM ETBusiness Wire
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
NewsFeb 1, 2:29 PM ETGianni di Poce
The Insider Report: Batten Down the Hatches
Press releaseJan 8, 4:05 PM ETBusiness Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsDec 15, 10:45 AM ETAvi Kapoor
Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday
NewsSep 22, 2:01 PM ET
Where Immunome Stands With Analysts
NewsSep 22, 10:42 AM ETAvi Kapoor
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
NewsSep 22, 8:53 AM ETAvi Kapoor
This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
NewsSep 5, 5:02 PM ET
Where Immunome Stands With Analysts
NewsMar 26, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsNov 8, 1:00 PM ET
Analyst Expectations For Immunome's Future

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome: Q4 Earnings Insights

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Immunome to Present at Upcoming Investor Conferences

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

The Insider Report: Batten Down the Hatches

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday

Where Immunome Stands With Analysts

This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Where Immunome Stands With Analysts

12 Health Care Stocks Moving In Wednesday's After-Market Session

Analyst Expectations For Immunome's Future